MEK1/2 Antibody | Affinity Biosciences

Product:	MEK1/2 Antibody
Catalog:	AF6385
Description:	Rabbit polyclonal antibody to MEK1/2
Application:	WB IHC IF/ICC
Reactivity:	Human, Mouse, Rat
Prediction:	Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.:	45kDa; 43kD,44kD(Calculated).
Uniprot:	Q02750 \| P36507
RRID:	AB_2835226

View similar products>>

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific.

Size	Price	Inventory
100ul	$280	In stock
200ul	$350	In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Related Downloads

MSDS

Data Sheet

COA

Protocols

WB Handbook

IHC Protocol

IF/ICC Protocol

Product Info

Source:

Rabbit

Application:

WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:

Human,Mouse,Rat

Prediction:

Pig(100%), Zebrafish(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(100%)

Clonality:

Polyclonal

Specificity:

MEK1/2 Antibody detects endogenous levels of total MEK1/2.

RRID:

AB_2835226
Cite Format: Affinity Biosciences Cat# AF6385, RRID:AB_2835226.

Conjugate:

Unconjugated.

Purification:

The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).

Storage:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

Alias:

Fold/Unfold

Dual specificity mitogen activated protein kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 1; ERK activator kinase 1; MAP kinase kinase 1; MAP kinase/Erk kinase 1; MAP2K1; MAPK/ERK kinase 1; MAPKK 1; MAPKK1; MEK 1; Mek1; MEKK1; Mitogen activated protein kinase kinase 1; MKK 1; MKK1; MP2K1_HUMAN; PRKMK1; Protein kinase mitogen activated kinase 1 (MAP kinase kinase 1); Protein kinase mitogen activated, kinase 1; Cardiofaciocutaneous syndrome; CFC syndrome; CFC4; Dual specificity mitogen activated protein kinase kinase 2; Dual specificity mitogen-activated protein kinase kinase 2; ERK activator kinase 2; FLJ26075; MAP kinase kinase 2; map2k2; MAPK / ERK kinase 2; MAPK/ERK kinase 2; MAPKK 2; MAPKK2; MEK 2; MEK2; Microtubule associated protein kinase kinase 2; Mitogen activated protein kinase kinase 2; Mitogen activated protein kinase kinase 2 p45; MKK 2; MKK2; MP2K2_HUMAN; OTTHUMP00000165826; OTTHUMP00000165827; PRKMK 2; PRKMK2;

Immunogens

Immunogen:

Uniprot:

Q02750(MP2K1_HUMAN) >>Visit HPA database.

P36507(MP2K2_HUMAN) >>Visit HPA database.

Gene(ID):

MAP2K1(5604) | MAP2K2(5605)

Expression:

Q02750 MP2K1_HUMAN:

Widely expressed, with extremely low levels in brain.

Description:

The protein encoded by this gene is a member of the dual specificity protein kinase family, which acts as a mitogen-activated protein (MAP) kinase kinase. MAP kinases, also known as extracellular signal-regulated kinases (ERKs), act as an integration point for multiple biochemical signals.

Sequence:

Q02750 MP2K1_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKVGELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSYGMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV

P36507 MP2K2_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRGLAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQGTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRPPGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADLKMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species

Results

Score

Pig

100

Horse

100

Bovine

100

Sheep

100

Dog

100

Xenopus

100

Zebrafish

100

Chicken

100

Rabbit

100

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q02750/P36507 As Substrate

P36507
Q02750

Site	PTM Type	Enzyme	Source
M1	Acetylation		Uniprot
K6	Ubiquitination		Uniprot
T13	Acetylation		Uniprot
S23	Phosphorylation		Uniprot
T25	Phosphorylation		Uniprot
S26	Phosphorylation	P36507 (MAP2K2)	Uniprot
S30	Phosphorylation		Uniprot
K40	Ubiquitination		Uniprot
K51	Ubiquitination		Uniprot
T59	Phosphorylation	O14757 (CHEK1)	Uniprot
K61	Ubiquitination		Uniprot
K63	Ubiquitination		Uniprot
K68	Ubiquitination		Uniprot
K88	Ubiquitination		Uniprot
S94	Phosphorylation		Uniprot
K101	Ubiquitination		Uniprot
K108	Sumoylation		Uniprot
K108	Ubiquitination		Uniprot
K163	Ubiquitination		Uniprot
K196	Ubiquitination		Uniprot
S198	Phosphorylation		Uniprot
K209	Ubiquitination		Uniprot
S216	Phosphorylation		Uniprot
S222	Acetylation		Uniprot
S222	Phosphorylation	P15056 (BRAF) , P41279 (MAP3K8) , O15530 (PDPK1) , P53350 (PLK1)	Uniprot
S226	Acetylation		Uniprot
S226	Phosphorylation	O15530 (PDPK1) , P53350 (PLK1) , P15056 (BRAF) , P41279 (MAP3K8) , P36507 (MAP2K2)	Uniprot
T230	Phosphorylation		Uniprot
S293	Phosphorylation		Uniprot
S295	Phosphorylation		Uniprot
S306	Phosphorylation		Uniprot
S312	Phosphorylation		Uniprot
K352	Ubiquitination		Uniprot
K361	Ubiquitination		Uniprot
K370	Ubiquitination		Uniprot
S372	Phosphorylation		Uniprot
K385	Ubiquitination		Uniprot
T394	Phosphorylation		Uniprot
T396	Phosphorylation	P36507 (MAP2K2)	Uniprot
T398	Phosphorylation		Uniprot

Site	PTM Type	Enzyme	Source
T23	Phosphorylation		Uniprot
S24	Phosphorylation	Q6VAB6 (KSR2)	Uniprot
S25	Phosphorylation		Uniprot
K36	Ubiquitination		Uniprot
T55	Phosphorylation	O14757 (CHEK1)	Uniprot
K57	Ubiquitination		Uniprot
K64	Ubiquitination		Uniprot
K70	Ubiquitination		Uniprot
S72	Phosphorylation	Q6VAB6 (KSR2)	Uniprot
K88	Ubiquitination		Uniprot
K97	Ubiquitination		Uniprot
K104	Sumoylation		Uniprot
K104	Ubiquitination		Uniprot
K168	Ubiquitination		Uniprot
K175	Acetylation		Uniprot
K175	Ubiquitination		Uniprot
K192	Ubiquitination		Uniprot
S194	Phosphorylation		Uniprot
K205	Ubiquitination		Uniprot
S212	Phosphorylation		Uniprot
S218	Phosphorylation	P53350 (PLK1) , O15530 (PDPK1) , P15056 (BRAF) , P41279 (MAP3K8) , Q5TCX8 (MAP3K21) , P00540 (MOS) , Q13233 (MAP3K1) , P10398 (ARAF) , P04049 (RAF1)	Uniprot
S222	Phosphorylation	Q5TCX8 (MAP3K21) , P10398 (ARAF) , Q13233 (MAP3K1) , P53350 (PLK1) , O15530 (PDPK1) , P00540 (MOS) , P04049 (RAF1) , P15056 (BRAF) , P41279 (MAP3K8)	Uniprot
T226	Phosphorylation		Uniprot
S231	Phosphorylation		Uniprot
S244	Phosphorylation	P41279 (MAP3K8)	Uniprot
S248	Phosphorylation	P41279 (MAP3K8)	Uniprot
T286	Phosphorylation	Q00535 (CDK5) , P06493 (CDK1) , P27361 (MAPK3) , P28482 (MAPK1)	Uniprot
T292	Phosphorylation	P06493 (CDK1) , P27361 (MAPK3) , Q00535 (CDK5) , P28482 (MAPK1)	Uniprot
S298	Phosphorylation	Q13153 (PAK1) , Q02750 (MAP2K1) , O75914 (PAK3)	Uniprot
S299	Phosphorylation		Uniprot
Y300	Phosphorylation	Q02750 (MAP2K1)	Uniprot
K344	Ubiquitination		Uniprot
K353	Ubiquitination		Uniprot
K362	Acetylation		Uniprot
S385	Phosphorylation		Uniprot
T386	Phosphorylation	P28482 (MAPK1) , P27361 (MAPK3)	Uniprot
T388	Phosphorylation		Uniprot

PTMs - Q02750/P36507 As Enzyme

P36507
Q02750

Substrate	Site	Source
P05787 (KRT8)	S74	Uniprot
P27361 (MAPK3)	T202	Uniprot
P27361 (MAPK3)	Y204	Uniprot
P28482 (MAPK1)	T185	Uniprot
P28482 (MAPK1)	Y187	Uniprot
P36507 (MAP2K2)	S26	Uniprot
P36507 (MAP2K2)	S226	Uniprot
P36507 (MAP2K2)	T396	Uniprot
P55211-1 (CASP9)	T125	Uniprot

Substrate	Site	Source
O75676-1 (RPS6KA4)	S196	Uniprot
O75676-1 (RPS6KA4)	S343	Uniprot
O75676-1 (RPS6KA4)	S347	Uniprot
O75676-1 (RPS6KA4)	S360	Uniprot
O75676-2 (RPS6KA4)	T562	Uniprot
O75676-1 (RPS6KA4)	T568	Uniprot
P04049 (RAF1)	S338	Uniprot
P05787 (KRT8)	S74	Uniprot
P15172 (MYOD1)	Y156	Uniprot
P17542 (TAL1)	S122	Uniprot
P27361 (MAPK3)	T202	Uniprot
P27361 (MAPK3)	Y204	Uniprot
P27361 (MAPK3)	T207	Uniprot
P27361 (MAPK3)	Y210	Uniprot
P28482 (MAPK1)	T185	Uniprot
P28482 (MAPK1)	Y187	Uniprot
P32121 (ARRB2)	T382	Uniprot
P35568 (IRS1)	S307	Uniprot
P37231 (PPARG)	S112	Uniprot
P49841 (GSK3B)	Y216	Uniprot
P55211-1 (CASP9)	T125	Uniprot
Q00613 (HSF1)	S326	Uniprot
Q02750 (MAP2K1)	S298	Uniprot
Q02750 (MAP2K1)	Y300	Uniprot
Q02750-1 (MAP2K1)	S304	Uniprot

Research Backgrounds

Q02750_MP2K1_HUMAN
P36507_MP2K2_HUMAN

Function:

Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation. Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis.

PTMs:

Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinase kinases (BRAF or MEKK1) positively regulates kinase activity. Also phosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK. MAPK1/ERK2 phosphorylation of Thr-292 occurs in response to cellular adhesion and leads to inhibition of Ser-298 phosphorylation by PAK.

Acetylation by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.

Subcellular Location:

Cytoplasm>Cytoskeleton>Microtubule organizing center>Centrosome. Cytoplasm>Cytoskeleton>Microtubule organizing center>Spindle pole body. Cytoplasm. Nucleus. Membrane>Peripheral membrane protein.
Note: Localizes at centrosomes during prometaphase, midzone during anaphase and midbody during telophase/cytokinesis (PubMed:14737111). Membrane localization is probably regulated by its interaction with KSR1 (PubMed:10409742).

Tissue Specificity:

Widely expressed, with extremely low levels in brain.

Subunit Structure:

Found in a complex with at least BRAF, HRAS, MAP2K1, MAPK3/ERK1 and RGS14 (By similarity). Forms a heterodimer with MAP2K2/MEK2 (By similarity). Forms heterodimers with KSR2 which further dimerize to form tetramers (By similarity). Interacts with KSR1 or KSR2 and BRAF; the interaction with KSR1 or KSR2 mediates KSR1-BRAF or KSR2-BRAF dimerization. Interacts with ARBB2, LAMTOR3, MAPK1/ERK2 and RAF1 (By similarity). Interacts with MORG1 (By similarity). Interacts with PPARG. Interacts with isoform 1 of VRK2. Interacts with SGK1. Interacts with BIRC6/bruce. Interacts with KAT7; the interaction promotes KAT7 phosphorylation (By similarity).

(Microbial infection) Interacts with Yersinia yopJ.

Family&Domains:

The proline-rich region localized between residues 270 and 307 is important for binding to RAF1 and activation of MAP2K1/MEK1.

Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.

Function:

Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases (By similarity). Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation.

PTMs:

MAPKK is itself dependent on Ser/Thr phosphorylation for activity catalyzed by MAP kinase kinase kinases (RAF or MEKK1). Phosphorylated by MAP2K1/MEK1 (By similarity).

Acetylation of Ser-222 and Ser-226 by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.

Subcellular Location:

Cytoplasm. Membrane>Peripheral membrane protein.
Note: Membrane localization is probably regulated by its interaction with KSR1.

Subunit Structure:

Interacts with MORG1 (By similarity). Interacts with SGK1. Interacts with KSR1. Interacts with KSR1 and BRAF; the interaction with KSR1 mediates KSR1-BRAF dimerization. Interacts with GLS.

Family&Domains:

Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.

Research Fields

· Cellular Processes > Cell growth and death > Oocyte meiosis. (View pathway)

· Cellular Processes > Transport and catabolism > Autophagy - animal. (View pathway)

· Cellular Processes > Cell growth and death > Apoptosis. (View pathway)

· Cellular Processes > Cell growth and death > Cellular senescence. (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion. (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Gap junction. (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Signaling pathways regulating pluripotency of stem cells. (View pathway)

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton. (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > ErbB signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > cGMP-PKG signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > FoxO signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Sphingolipid signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Phospholipase D signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > mTOR signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Apelin signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway. (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Neurodegenerative diseases > Prion diseases.

· Human Diseases > Substance dependence > Alcoholism.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Colorectal cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Renal cell carcinoma. (View pathway)

· Human Diseases > Cancers: Specific types > Pancreatic cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Endometrial cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Glioma. (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Thyroid cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma. (View pathway)

· Human Diseases > Cancers: Specific types > Bladder cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia. (View pathway)

· Human Diseases > Cancers: Specific types > Acute myeloid leukemia. (View pathway)

· Human Diseases > Cancers: Specific types > Non-small cell lung cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma. (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer. (View pathway)

· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer. (View pathway)

· Human Diseases > Cancers: Overview > Choline metabolism in cancer. (View pathway)

· Organismal Systems > Immune system > Chemokine signaling pathway. (View pathway)

· Organismal Systems > Circulatory system > Vascular smooth muscle contraction. (View pathway)

· Organismal Systems > Development > Osteoclast differentiation. (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity. (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > B cell receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > Fc epsilon RI signaling pathway. (View pathway)

· Organismal Systems > Immune system > Fc gamma R-mediated phagocytosis. (View pathway)

· Organismal Systems > Nervous system > Long-term potentiation.

· Organismal Systems > Nervous system > Neurotrophin signaling pathway. (View pathway)

· Organismal Systems > Nervous system > Cholinergic synapse.

· Organismal Systems > Nervous system > Serotonergic synapse.

· Organismal Systems > Nervous system > Long-term depression.

· Organismal Systems > Endocrine system > Insulin signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Progesterone-mediated oocyte maturation.

· Organismal Systems > Endocrine system > Estrogen signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Melanogenesis.

· Organismal Systems > Endocrine system > Prolactin signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Oxytocin signaling pathway.

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

References

1). Tanshinone IIA inhibits cardiomyocyte apoptosis and rescues cardiac function during doxorubicin-induced cardiotoxicity by activating the DAXX/MEK/ERK1/2 pathway. Phytomedicine, 2022 (PubMed: 36182795) [IF=7.9]

2). Serum proteomics analysis based on label-free revealed the protective effect of Chinese herbal formula Gu-Ben-Fang-Xiao. BIOMEDICINE & PHARMACOTHERAPY, 2019 (PubMed: 31520916) [IF=7.5]

Application: WB Species: mouse Sample: lung

Figure S2. |The effect of GBFXD on RAF/MEK/ERK signaling pathway. Western blotting was used to detect the relative protein expressions of P-RAF/RAF, P-MEK/MEK, and P-ERK/ERK.

3). Antimalarial drug pyrimethamine plays a dual role in anti-tumor proliferation and metastasis through targeting DHFR and TP. MOLECULAR CANCER THERAPEUTICS, 2019 (PubMed: 30642883) [IF=5.7]

Application: WB Species: human Sample: NCI-H460 cells

Figure 6.| Pyr can bind to TP and inhibit TP-induced migration, invasion, and EMT of lung cancer cells. (A) Molecular docking results for TP and Pyr. (B) Thymine concentration of NCI-H460 cells treated with 5-UIR, Pyr, and MTX. Intercellular thymine concentration was used as an index of TP activity. (C) Interaction between Pyr and TP verified through Biacore assay (Kd=6.19±0.78 μM). (D) Pyr can inhibit the TP-induced migration of cancer cells. Wound-healing assay was used in this experiment. (E) Pyr can inhibit the TP-induced invasion of cancer cells. Transwell chambers were utilized for the invasion assay, and images were obtained under 200× magnification. (F) E-cadherin, vimentin, MEK2, and ERK2 expression levels of NCI-H460 cells in different treatment groups. The GAPDH blot served as the loading control. Data are presented as the means of three experiments, and error bars represent the standard deviation (*P < 0.05, **P < 0.01)

4). Intra-Pancreatic Insulin Nourishes Cancer Cells: Do Insulin-Receptor Antagonists such as PGG and EGCG Play a Role?. The American Journal of Chinese Medicine, 2020 (PubMed: 32468825) [IF=5.7]

Application: WB Species: Mice Sample: tumors tissue

Figure 4. See the legend of Fig. 3 for study design. (A, B) t-Akt and p-Akt results from the sub-studies that involved PGG (A) and EGCG (B). (C, D) t-MEK and p-MEK results from the sub-studies that involved PGG (C) and EGCG (D). (E, F) t-ERK1/2 and p-ERK1/2 results from the sub-studies that involved PGG (E) and EGCG (F). β-Actin was used as a loading control. The blotting data are derived from representative tumors. The histograms include data from all tumors. *p < 0:05.

5). l-Theanine attenuates neointimal hyperplasia via suppression of vascular smooth muscle cell phenotypic modulation. JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2020 (PubMed: 32402912) [IF=5.6]

6). Wenshen-Jianpi prescription, a Chinese herbal medicine, improves visceral hypersensitivity in a rat model of IBS-D by regulating the MEK/ERK signal pathway. Frontiers in Pharmacology, 2022 (PubMed: 36210803) [IF=5.6]

7). β-Patchoulene Ameliorates Water Transport and the Mucus Barrier in 5-Fluorouracil-Induced Intestinal Mucositis Rats via the cAMP/PKA/CREB Signaling Pathway. Frontiers in Pharmacology, 2021 (PubMed: 34512326) [IF=5.6]

Application: WB Species: Rat Sample:

FIGURE 5 Effects of β-PAE on AQP3 expression and cAMP/PKA/CREB signaling pathway-related proteins. (A,B) AQP3 expression; (C,D) VIP, VIPR2, cAMP and PKA expression; (E,F) MEK1/2, p-MEK1/2, ERK, p-ERK, p-p38, p38, MSK1, p-MSK1, CREB, p-CREB, and P300/CBP expression. Data are shown as mean ± SD (n = 3). # p < 0.05, ## p < 0.01 versus control group; * p < 0.05, ** p < 0.01 versus 5-FU group.

8). Loganin alleviates sepsis-induced acute lung injury by regulating macrophage polarization and inhibiting NLRP3 inflammasome activation. International Immunopharmacology, 2021 (PubMed: 33744777) [IF=5.6]

Application: WB Species: Mice Sample: lung tissues

Fig. 5. Loganin inhibits ERK and NF-κB signaling in sepsis-induced ALI mice. (A) The levels of pro-inflammatory cytokines TNF-α and IL-6 in BALF were measured by ELISA assay. (B) The expression of Bcl-2 and Bcl-xl were detected by western blotting. (C) The expression of MEK, p-MEK (Ser217/ Ser221), ERK, p-ERK (Thr202/Tyr204), IKK-α/β, p-IKK-α/β (Ser180/Ser181), IκB-α, p-IκB-α (Ser32/36), NF-κB p65 (cytoplasm), NF-κB p65 (nucleus) were determined by western blotting. Data were shown as means ± SD. n = 6. *p < 0.05 vs. sham. #p < 0.05 vs. CLP. ERK, extra-cellular signal-regulated kinase; NF-κB, nuclear factor-kappa B; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; BALF, bronchoalveolar lavage fluid; CLP, cecal ligation and puncture.

9). Circ_0011385 knockdown inhibits cell proliferation, migration and invasion, whereas promotes cell apoptosis by regulating miR-330-3p/MYO6 axis in colorectal cancer. Biomedical Journal, 2023 (PubMed: 35091088) [IF=5.5]

10). Mechanisms of pancreatic tumor suppression mediated by Xiang-lian pill: An integrated in silico exploration and experimental validation. JOURNAL OF ETHNOPHARMACOLOGY, 2022 (PubMed: 35931303) [IF=5.4]

Application: WB Species: Mouse Sample:

Fig. 6. XLP suppressed pancreatic tumor growth of tumor-bearing mice. (A) Tumors of mice in different groups treated with different doses of XLP; (B) Tumor weights among different groups; (C) Tumor volume increased over time; (D) HE staining of mouse liver and kidney tissues; (E) Mouse body weight over time; (F) Tumor pathology among four groups under microscopy (HE, 200 × ), and the expression of Ki-67, PTGS2 and PTGS1 among four groups (IHC, 400 × ); (G) Quantitation of the IHC positive area of Ki-67, PTGS2 and PTGS1 in the tumor tissues of four groups (n = 8 each group, each dot represents one sample); (H) The expression of PTGS1 and PTGS2, the phosphorylation of MEK and ERK among four groups by immunoblotting; (I) Statistical analysis of the immunoblotting results. * denotes p < 0.05, ** p < 0.01 and *** p < 0.001 when compared with the control group; # denotes p < 0.05, ## p < 0.01 and ### p < 0.001 when compared with the 0.78 g/kg XLP group.

Restrictive clause

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.

MEK1/2 Antibody - #AF6385